Becton, Dickinson and Company (NYSE:BDX) announces that its newly developed molecular test for detecting harmful intestinal bacteria causing infectious diarrhea has received 510(k) clearance from the FDA.
The BD MAX extended enteric bacterial panel is the latest offering in the suite of BD MAX enteric assays, which aid in the detection and diagnosis of acute gastroenteritis. This panel enables individualized testing to be performed based on a patient's symptoms and health history.
Now read: Preferred Stock IPOs For May 2017 »
Subscribe for full text news in your inbox